GRI Bio Inc. (GRI NASDAQ) stock market data APIs
$1.5753
0.08(5.1%)
as of July 10, 2025
Try our APIs with
free plan!
GRI Bio Inc. Financial Data Overview
Price chart is built with
Anychart
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Prev. Close
1.5753
Open
1.6592
High
1.7474
Low
1.5515
52 wk Range
1.1-32.98
Market Cap
3 896 K
P/E Ratio
0.0414
Shares Outstanding
2 347 K
EPS
-5.8
Beta
-2.105
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GRI Bio Inc. data using free add-ons & libraries
Get GRI Bio Inc. Fundamental Data
GRI Bio Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -9 387 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-15
- EPS/Forecast: -3.78
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GRI Bio Inc. News
New
U.K.'s Grainger's flagship BTR site in Oxford exceeds leasing expectations
Investing.com -- Grainger Plc (LON:GRI) announced that its first build-to-rent (BTR) site in Oxford, The Kimmeridge, has achieved approximately 60% lease-up in just three months since its launch in ea...
Oxford's first build-to-rent scheme reaches 60% occupancy in three months
OXFORD - Grainger plc, the UK’s largest listed residential landlord, announced Wednesday that its Oxford development has reached approximately 60% occupancy within three months of its March 2025 lau...
Norges Bank reduces stake in Grainger to 8.99%
LONDON - Norges Bank has decreased its voting rights in UK residential landlord Grainger PLC (LSE:GRI) to 8.99% from 9.08%, according to a regulatory filing released Monday. The Norwegian central ban...
GRI Bio stock holds Buy rating at H.C. Wainwright as Phase 2a trial completes enrollment
Investing.com - GRI Bio, Inc. (NASDAQ:GRI), a clinical-stage biotech company with a market capitalization of $3.22 million, has completed enrollment in its Phase 2a clinical trial evaluating GRI-0621 ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
